References
- Freston JW, Malagelada JR, Peterson H, McCloy RF. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995;7:577–86.
- Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology 1992;39:322–4.
- Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996;18:2–35.
- Mears JM, Kaplan B. Proton pump inhibitors: new drugs and indications. Am Fam Physician 1996;53:285–92.
- Holt S. Proton pump inhibition for acid related disease. South Med J 1991;84:1078–87.
- Prakash A, Faulds D. Rabeprazole. Drugs 1998;55:261–7.
- Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997;11:973–80.
- Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438–46.
- Cloud ML, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebocontrolled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998;43:993–1000.
- Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999;13(1): 49–57.
- Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988;95:903–12.
- General Well-Being Schedule, MAPI Values, Manchester, UK.
- Donner A. Approaches to sample size estimation in the design of clinical trials—a review. Stat Med 1984;3:199–214.
- Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci 2000;45:845–53.
- Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079–89.